Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vYF Yellow Fever Vaccine Dose-Ranging Study in Adults
NCT04142086Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of SP0218 in yellow fever (4 arms), sponsored by Sanofi. Primary endpoints: Immediate Adverse Events at 30 minutes, Solicited Injection Site Reactions at 7 days and 11 more. Started Jan 2020; status: completed.
02
Drugs
SP0218
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT04142086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142086.